Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05651880 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy and Tolerance of Baricitinib, a JAK Inhibitor, in the Treatment of Refractory Non-infectious Non-anterior Uveitis

Study acronym: JAKUVEITE
StatusNot Yet Recruiting
PhasePhase 3
Started2026-07
View on ClinicalTrials.gov ↗

Amendment history

2026-06-05
Study Status, Contacts/Locations v2
Primary completion pushed: 2029-08 → 2029-12
Completion pushed: 2029-08 → 2029-12
Start date2026-03→2026-07
Study sites0→1
2026-02-05
Study Status v1
Primary completion date2023-08-01→2029-08
Completion date2026-08-01→2029-08
Start date2023-02-01→2026-03
2022-12-07
Original filing
The aim of the study is to evaluate the efficacy of Baricitinib, a JAK1 and 2 inhibitor, in the management of non-infectious non-anterior uveitis refractory to at least one line of biotherapy (anti-TNF alpha, tocilizumab) after 6 months of treatment
Trial Details
NCT Number NCT05651880
Lead Sponsor University Hospital, Rouen
Conditions Active Non-anterior Non-infectious Uveitis
Enrollment 33 participants
Start Date 2026-07
Primary Completion 2029-12 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2026-06-08